SpringWorks Therapeutics Announces Phase Ib/IIa Clinical Trial of Mirdametinib in Patients with Advanced Solid Cancers Harboring MAPK-Activating Mutations

SpringWorks Therapeutics, Inc. announced that the company will be evaluating mirdametinib, an investigational MEK inhibitor, in a platform study exploring the compound both as a monotherapy and as a combination therapy in advanced solid tumors harboring MAPK-activating mutations.